Table 1.
Characteristics of the major clinical studies of dasatinib treatment with CML patients.
| Study | Treatment option | Treatment (N) | Follow time (years) | |||
|---|---|---|---|---|---|---|
| Arm 1 | Arm 2 | Arm 3 | Arm 4 | |||
| MDACC trail | First-line | Dasatinib (100mg daily, N=66) | Dasatinib (50mg bid, N=33) | NA | NA | 1 y |
| DASISION trail | First-line | Dasatinib (100mg daily, N=258) | Imatinib (400 mg daily, N=258) | NA | NA | 1 y |
| DASISION trail | First-line | Dasatinib (100mg daily, N=258) | Imatinib (400 mg daily, N=258) | NA | NA | 2 y |
| DASISION trail | First-line | Dasatinib (100mg daily, N=258) | Imatinib (400mg daily, N=258) | NA | NA | 5 y |
| NordCML006 trail | First-line | Dasatinib (100mg daily, N=22) | Imatinib (400mg daily, N=24) | NA | NA | 3 y |
| START-R | Second-line | Dasatinib (70mg bid, N=101) | Imatinib (400mg bid, N=49) | NA | NA | 2 y |
| CA180-034 | Second-line | Dasatinib (100mg daily, N=167) | Dasatinib (50mg bid, N=168) | Dasatinib (140mg daily, N=167) | Dasatinib (70 mg bid, N=168) | 2 y |
| CA180-034 | Second-line | Dasatinib (100mg daily, N=167) | Dasatinib (50mg bid, N=168) | Dasatinib (140mg daily, N=167) | Dasatinib (70 mg bid, N=168) | 7 y |
| DASCERN | Second-line | Dasatinib (100mg daily, N=174) | Imatinib (≥400mg daily, N=86) | NA | NA | 2 y |
| Abhishek Maiti | First-line | Dasatinib (100mg daily, N=149) | NA | NA | NA | 11 y |
NA, Not applicable.